Glenmark interim dividend ₹2.50: Record date Oct 3, 2025

Overview: what Glenmark announced

Glenmark Pharmaceuticals has declared an interim dividend of ₹2.50 per equity share for FY2025-26. The record date and the ex-dividend date are both set as Friday, October 3, 2025. The update matters for investors because share ownership around the record date determines eligibility for the payout. The announcement was shared through exchange filings, with the company noting that the dividend will be paid within 30 days of declaration. Separately, investor guidance notes that dividend credits can typically reflect in the bank account linked to the Demat account within 25 to 45 business days after the record date.

Dividend size, face value, and aggregate outgo

The interim dividend is ₹2.50 per equity share. Glenmark’s filing specifies the face value of the equity share as Re 1. Along with the per-share payout, the filing also mentioned the approximate aggregate outgo for the dividend. The total cash outflow for this interim dividend is about ₹70.55 crore (approximately ₹705.50 million). This figure provides a sense of the company’s total distribution for the declared interim payout, based on its outstanding equity base.

Key dates investors should track

The company has set October 3, 2025 as the record date for determining eligible shareholders. The ex-dividend date is also October 3, 2025, based on the corporate action information shared. Investors who own the shares on or before the record date will be eligible to receive the dividend. If an investor purchases the stock on or after the ex-dividend date, they will not be entitled to the declared dividend. The alignment of ex-date and record date is a key detail because it narrows the window for eligibility checks.

What the exchange filing and board outcome stated

As per the exchange filing dated September 26, 2025, the board approved the interim dividend of ₹2.50 per equity share for FY2025-26. The corporate communication around the board meeting also described the item as an “Outcome of the Board Meeting,” referring to the interim dividend approval and related corporate governance actions such as committee reconstitution. The filing specifies the record date as Friday, October 3, 2025. It also states that the interim dividend will be paid within 30 days from the date of declaration.

Record date revision: what changed

The material also references that Glenmark revised the record date to October 3, 2025 for the interim dividend. The board meeting to consider and approve the interim dividend remained scheduled for September 26, 2025. The company communicated the revision to both BSE and NSE, and the disclosure notes that the process aligns with SEBI regulations. For investors, the revision point is mainly operational, but it is important because record date changes can affect who qualifies for the payout.

How eligibility works around the ex-dividend date

Eligibility is tied to the shareholder list as of the record date set by the company. The record date is when Glenmark identifies eligible shareholders for dividend payment. Because the ex-dividend date is October 3, 2025, buying shares on or after that date means the buyer does not receive this dividend. Conversely, shareholders who already hold the shares on or before the record date remain eligible, as per the guidance provided in the material. This is why the ex-date and record date need to be checked carefully ahead of a dividend.

When investors can expect the dividend credit

The exchange filing states that the dividend will be paid within 30 days of declaration. Investor-facing guidance in the material also notes that dividend receipts can reach the bank account linked to a Demat account within 25 to 45 business days after the record date. These timelines are consistent with the practical process of corporate action execution, including confirmation of eligible shareholders and completing payment through the banking and depository systems. Investors typically track the record date for eligibility and then monitor communication from the company or exchanges for the payment date.

Glenmark’s recent dividend history (from the provided data)

The same material includes references to past dividend entries, including earlier payouts at ₹2.50 per share. It also lists a final dividend declared earlier with an ex-date and record date of September 15, 2025 at ₹2.50 per share. Additionally, it references a cash dividend of ₹2.50 with an ex or effective date of September 13, 2024 and a record date of September 17, 2024.

Market snapshot mentioned in the material

The provided data includes a Glenmark Pharma price snapshot of ₹2,364.2, down 1.20%, timestamped May 22, 2026 at 04:09:58 PM. This snapshot is not tied to the September 2025 dividend declaration date, but it is part of the same compiled information set. Investors generally track the share price around corporate actions to understand market positioning and liquidity, although the material does not provide a specific price move linked to the dividend announcement.

Market Impact

The direct market relevance here is the dividend eligibility window created by the ex-dividend date and record date on October 3, 2025. For shareholders, the key impact is whether they appear on the company’s records as of the record date, which determines entitlement to ₹2.50 per share. The aggregate outgo of about ₹70.55 crore (₹705.50 million) indicates the size of cash distribution linked to this interim dividend decision. The filing-based payout timeline of within 30 days also sets an execution expectation for investors tracking dividend receipts.

Analysis: why this dividend update matters

The announcement provides clarity on corporate action dates, which is essential for investors who rely on dividend income or manage positions around record dates. The interim dividend format also reflects that the company is distributing cash during the financial year, rather than only after final accounts. The material explicitly frames the dividend as part of Glenmark’s ongoing shareholder distributions, and the repeated ₹2.50 entries across multiple periods show a consistent per-share level in the cited records. For investors, the most actionable takeaway remains operational: aligning buy and sell decisions with the ex-dividend date and verifying eligibility on the record date.

Conclusion

Glenmark Pharmaceuticals has declared an interim dividend of ₹2.50 per share for FY2025-26, with October 3, 2025 set as both the record date and the ex-dividend date. The company has stated that the dividend will be paid within 30 days of declaration, and other guidance indicates investors may see credits within 25 to 45 business days after the record date. Shareholders will watch for the company’s subsequent communication on the actual payment date and completion of the corporate action process through the exchanges and depositories.